Virpax Pharmaceuticals (VRPX) 10-Q2023 Q1 Quarterly report

Filed: 12 May 23, 4:15pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: advisory, appeal, bank, banking, bid, billion, CDER, classification, conflict, consecutive, contoured, DAV, deficiency, degradant, delisting, Department, Deputy, doubt, encapsulate, epilepsy, exceeded, exploit, exploring, fail, FDIC, fifteenth, Fioravanti, forced, healthcare, high, hour, inclusive, infection, infiltrating, mechanism, metered, minimum, mitigate, mitigating, Nasdaq, newly, NobrXiol, NobrXiolTM, nonclinical, nonprescription, notification, orthopedic, panel, paragraph, permeation, post, pre, prescribe, produced, publicly, recommended, regain, reimbursement, reputable, responding, reverse, Russia, securing, site, split, unique, war, worsening

Removed: absorption, accounted, adjuvant, allege, allocated, assay, belief, belonging, breaching, Canada, case, ceased, chemical, Chipman, Christopher, Cmax, combat, commerce, component, concentration, confirming, contemplated, convertible, COVID, CTA, curved, deducting, defer, deferring, demand, demonstrated, dermal, direct, disrupted, effort, enrollment, entitled, entity, epidemic, equipment, evolve, executed, fallen, fearful, furnished, guinea, hand, herewith, hydrogel, indirect, inhibited, initially, investor, IPO, irritation, leading, maximum, mobility, modify, monthly, mouse, negotiate, Newburyport, opioid, outbreak, pandemic, parallel, personal, pharmacokinetic, phototoxicity, PK, plasma, production, promissory, protective, reached, remain, remained, remedied, repaid, repayment, replication, reportable, representing, RRD, run, salary, scheduled, sensitization, skin, slight, spiked, spread, submit, suspended, temporarily, therapy, tissue, tolerated, Topic, transdermal, travel, traveling, treated, underwriting, underwritten, validation, volatile, weight, worker

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

VRPX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Virpax Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of Anthony Mack, as Chief Executive Officer, and Christopher Chipman, as Chief Financial Officer, certifies in his capacity as such officer of the Company, that to such officer’s knowledge, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 12, 2023

	By:	/s/ Anthony P. Mack
		Anthony P. Mack
		Chief Executive Officer
		(Principal Executive Officer)

	By:	/s/ Christopher Chipman
		Christopher Chipman
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.